AI Article Synopsis
- In a clinical trial involving 43 virologically suppressed patients, participants were randomized into three groups: monotherapy with darunavir/ritonavir (DRV/r), monotherapy with lopinavir/ritonavir (LPV/r), or continued standard antiretroviral therapy (cART).
- At week 48, the success rates for maintaining viral suppression were 73% for DRV/r, 69% for LPV/r, and 87% for cART, indicating that cART had the highest success rate.
- The LPV/r group had one case of virological failure and experienced a slight decline in lipid levels, highlighting some potential side effects compared to the other treatment options.
Article Abstract
In a multicentre, open-label, clinical trial, 43 patients virologically suppressed while receiving a standard triple antiretroviral therapy were randomized (1:1:1) to switch to monotherapy with darunavir/ritonavir (DRV/r-MT arm), monotherapy with lopinavir/ritonavir (LPV/r-MT arm) or to continue on the ongoing regimen (cART arm). The proportion (95% CI) of patients with virological success (Snapshot analysis) at week 48 was 73% (48%-90%) in the DRV/r-MT arm, 69% (42%-88%) in the LPV/r-MT arm and 87% (61%-98%) in the cART arm. Virological failure was detected in only one patient receiving LPV/r-MT. The LPV/r-MT arm showed a modest worsening in lipid profile.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!